Mobile Observation Of Depression (MOOD) platform for digital phenotyping

用于数字表型分析的抑郁症移动观察 (MOOD) 平台

• 批准号: 105207
• 金额: $ 68.93万
• 依托单位: EMTEQ LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=105207
• 关键词: Mobile; Observation; Depression; MOOD; platform

"Emteq Ltd, based at the Sussex Innovation Centre, is developing a wearable digital platform that allows real-time objective monitoring of novel markers of depression.The World Health Organization (WHO) estimates more than 300m people are living with depression. In the UK, up to 10% of people will suffer from depression at some point in their lives; accounting for over 57m annual antidepressant prescriptions (England, 2014). The rising incidence of depression worldwide is attributed to increased stress and changing lifestyle. The economic cost of treating a patient with depression is £2,085/person/year and productivity losses account for £7.5b annually.Most precision medicine approaches look for genetic or molecular disease markers. However, whilst some conditions such as cystic fibrosis have and strong genetic influence, twin studies show that for the top ten causes of preventable deaths, genes contribute only a minor predictive role. All of the top ten causes of premature death have a strong behavioural influence, therefore predictive analytics based on digital phenotyping has huge potential to save lives.Currently, no technology is available for clinicians to measure emotional responses objectively in people with major depression. In clinical practice, assessment and documentation of symptoms and signs relies on the patients' subjective recall and a 'snapshot' of how they are feeling on the day. In this respect, a system for objective monitoring during day-to-day activities could have a tremendous impact on treatment stratification and compliance, and understanding individual drivers of happiness.We are collaborating with leading specialists in mental health (MindTech, Sussex Partnership NHS Trust), to develop the 'MOOD' platform for use in patient diagnosis, stratification and treatment monitoring.Sussex Partnership NHS Trust operates from over 260 sites, including community services, and serves a population of 1.55 million people. MindTech is instrumental in ensuring adequate Public Patient Representation, user interface design and advice on clinical pathways.We have invested heavily in building an international network of commercial and academic partners. Successful project delivery will cement our reputation as leading innovators within the industry and is the first step in an ambitious commercial strategy to disrupt the depression treatment and screening markets."

“总部位于苏塞克斯创新中心的 Emteq Ltd 正在开发一款可穿戴数字平台，可以实时客观监测新的抑郁症标志物。世界卫生组织 (WHO) 估计有超过 3 亿人患有抑郁症。在英国，高达 10% 的人会在一生中的某个阶段患上抑郁症；每年开出的抗抑郁药处方数量超过 5700 万张（英格兰，2014 年）。全球抑郁症发病率不断上升， 归因于压力增加和生活方式的改变。治疗抑郁症患者的经济成本为 2,085 英镑/人/年，生产力损失每年高达 7.5 亿英镑。大多数精准医学方法都会寻找遗传或分子疾病标记。然而，虽然囊性纤维化等某些疾病具有很强的遗传影响，但双胞胎研究表明，对于可预防死亡的十大原因，基因仅发挥很小的预测作用。所有的 过早死亡的十大原因对行为有很强的影响，因此基于数字表型的预测分析具有拯救生命的巨大潜力。目前，临床医生还没有技术可以客观地测量重度抑郁症患者的情绪反应。在临床实践中，症状和体征的评估和记录依赖于患者的主观回忆和他们当天感受的“快照”。在这方面，需要建立一个在日常过程中进行客观监控的系统。 活动可能会对治疗分层和依从性以及了解个人幸福感的驱动因素产生巨大影响。我们正在与心理健康领域的领先专家（MindTech、Sussex Partnership NHS Trust）合作，开发用于患者诊断、分层和治疗监测的“MOOD”平台。Sussex Partnership NHS Trust 在 260 多个站点开展业务，包括社区服务，为 155 万人提供服务。 MindTech 发挥了重要作用 确保足够的公众患者代表、用户界面设计和临床路径建议。我们投入巨资建立商业和学术合作伙伴的国际网络。成功的项目交付将巩固我们作为行业领先创新者的声誉，也是颠覆抑郁症治疗和筛查市场的雄心勃勃的商业战略的第一步。”